DEA Bans Five Sneaky Benzo Drugs in Schedule I Crackdown
Published Date: 7/25/2025
Proposed Rule
Summary
The DEA wants to make it official: clonazolam, diclazepam, etizolam, flualprazolam, and flubromazolam will stay in Schedule I, meaning they’re illegal to make, sell, or use without special permission. This change affects anyone handling these drugs and keeps the rules strict, matching international drug laws. If approved, these tough rules will last beyond July 2026, with no new costs for most people.
Analyzed Economic Effects
2 provisions identified: 1 benefits, 1 costs, 0 mixed.
Five Drugs Permanently Placed in Schedule I
If you handle clonazolam, diclazepam, etizolam, flualprazolam, or flubromazolam (including their salts and isomers), this proposed rule would place them in Schedule I so they are illegal to manufacture, distribute, import, export, research, teach about, chemically analyze, or possess without special permission. These substances were temporarily scheduled on July 26, 2023 and the temporary scheduling was extended until July 26, 2026; if finalized the rule would make those Schedule I controls permanent.
Rule Says No New Costs For Most People
If finalized, the rule states there will be no new costs for most people even though the five substances would remain in Schedule I beyond July 26, 2026. You (as a typical member of the public) would generally not face new financial requirements from this action.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-10128 — Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2026-10253 — Schedules of Controlled Substances: Temporary Placement of 2-Fluorodeschloroketamine in Schedule I
Starting May 22, 2026, the DEA is putting 2-fluorodeschloroketamine (2-FDCK) into Schedule I, meaning it’s now treated like the most dangerous drugs. This affects anyone who makes, sells, or uses it, adding strict rules and serious penalties. The temporary ban lasts two years, giving the government time to decide if it should stay permanent.
2026-10090 — Exempt Chemical Preparations Under the Controlled Substances Act
The Drug Enforcement Administration (DEA) reviewed and decided on applications for special chemical mixtures that don’t fall under strict drug rules, covering requests from July 2025 to March 2026. Some mixtures got approved, others denied, and a few listings were fixed from earlier notices. If you’re involved with these chemicals, you’ve got until July 20, 2026, to share your thoughts—no fees or big costs involved, just your voice!
2026-09566 — Schedules of Controlled Substances: Placement of CUMYL-PEGACLONE in Schedule I
Starting May 13, 2026, the DEA officially puts CUMYL-PEGACLONE—a chemical that can be risky—into Schedule I, the strictest drug category. This means anyone making, selling, or using it now faces tough rules and penalties. This move helps the U.S. follow international drug laws and keeps communities safer without any new fees or costs.
2026-08587 — Importer of Controlled Substances Application: ANI Pharmaceuticals Inc.
ANI Pharmaceuticals wants to import certain controlled drugs like Levorphanol and Tapentadol. People who make or use these drugs can share their thoughts or ask for a hearing by June 3, 2026. This move could affect drug availability and regulation, so keep an eye on the deadline to have your say!
2026-08588 — Bulk Manufacturer of Controlled Substances Application: Patheon API Inc.
Patheon API Inc. wants to make large amounts of special research drugs like dimethyltryptamine and psilocybin. This affects researchers and companies involved in clinical trials, with a chance to comment or ask for a hearing by July 6, 2026. No money changes are mentioned, but this move could speed up important medical studies.
Previous / Next Documents
Previous: 2025-14001 — Amendment of Class D Airspace and Establishment of Class E2 Airspace Over Hampton Roads, VA
Pilots flying near Langley Air Force Base in Hampton Roads, VA, will see changes as the air traffic control tower moves to part-time hours. The government is updating the airspace rules to keep flights safe and smooth, including new boundaries and coordinates. These changes help manage flights better without extra costs or delays.
Next: 2025-14060 — Regulatory Publication and Review Under the Economic Growth and Regulatory Paperwork Reduction Act of 1996
The OCC, Board, and FDIC are teaming up to review and clean up old banking rules that might be outdated or unnecessary for banks and their parent companies. Since early 2024, they've asked for public feedback in several steps, and now they're focusing on the last set of rules about banking operations, capital, and community support. This review aims to make regulations simpler and more efficient by July 2025, helping banks save time and money.